SCHEMBL5316687

SCHEMBL5316687

CNS(=O)(=O)c1nccc(N(C)c2cccc(-c3ccccc3)n2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ IKBKB O14920 2/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ BPTF Q12830 1/20 0.35
▸ KAT6A Q92794 1/20 0.35
▸ KDR P35968 4/20 0.34
▸ CA12 O43570 2/20 0.34
▸ CA1 P00915 2/20 0.34
▸ CA2 P00918 2/20 0.34
▸ CA5A P35218 2/20 0.34
▸ CA9 Q16790 2/20 0.34
▸ CA5B Q9Y2D0 2/20 0.34
▸ ATR Q13535 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5914145 0.88 IKBKB (0.37) LMNATP53CYP1A2CYP3A4CYP2C9
SCHEMBL5914109 0.73 MEN1 (0.41) LMNATP53SMN1; SMN2MEN1RAB9A
SCHEMBL5914113 0.71 MEN1 (0.39) LMNATP53CYP1A2CYP3A4CYP2C9
SCHEMBL4004337 0.71 KDR (0.34) LMNACYP3A4CYP2C9IKBKBMEN1
SCHEMBL5914156 0.69 HTR7 (0.46) KDRCDK2HTR2AHTR7
SCHEMBL20684698 0.67 MEN1 (0.56) TP53SMN1; SMN2MEN1RAB9AKMT2A
SCHEMBL20684697 0.67 MEN1 (0.60) TP53SMN1; SMN2MEN1RAB9AKMT2A
SCHEMBL4447801 0.65 BPTF (0.54) LMNATP53CYP1A2CYP3A4CYP2C9
SCHEMBL19272769 0.64 MEN1 (0.50) TP53SMN1; SMN2MEN1RAB9AKMT2A
SCHEMBL31206017 0.63 CA12 (0.41) LMNASMN1; SMN2RAB9ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1794135-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-06-13 — — EP disclosed
WO-2006037117-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-04-06 — — WO disclosed
Send feedback